Cinven's Amco in bolt-on
Cinven portfolio company Amdipharm Mercury (Amco) has acquired Abcur, a Swedish pharmaceutical business.
Abcur has previously been the distributor of Amco's products, including glaucoma treatment drug Diamox.
The bolt-on is part of Amco's expansion strategy of creating a consolidated international speciality pharmaceutical business via both organic growth and acquisitions.
Cinven acquired Mercury Pharma from Hg Capital in August 2012 for an enterprise value of £465m. In October 2012, family-owned speciality pharmaceuticals business Amdipharm was acquired for a total consideration of £367m. Cinven later merged the two entities.
The investment in Amco was made from Cinven's fifth European buyout fund, which closed on €5.3bn in June 2013.
Company
Founded in 2006 and headquartered in Helsingborg, Sweden, Abcur is a speciality pharmaceutical business developing, registering and marketing specialised prescription and non-prescription products for addiction, intensive care, pain management and anaesthesia. The company operates in Sweden, Finland, Norway, Denmark and Iceland.
People
John Beighton is the chief executive of AmCo. Roger Tapper is the founder of Abcur; he will now be joining Amco along with the rest of the management team.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








